<DOC>
	<DOCNO>NCT00108108</DOCNO>
	<brief_summary>The purpose study determine high tolerate dose , safety activity HCD122 patient chronic lymphocytic leukemia relapse receive prior treatment .</brief_summary>
	<brief_title>Dose-finding Trial HCD122 Patients With Chronic Lymphocytic Leukemia ( CLL ) That Relapsed Non-responsive Prior Fludaribine Therapy</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Clinical diagnosis CLL require treatment Refractory relapse disease Prior treatment fludarabine Male Female &gt; 18 year age Treatment rituximab within 90 day alemtuzumab monoclonal antibody within 6 month . Clinically significant cardiac dysfunction significant organ dysfunction Additional eligibility criterion apply review potential study subject site .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Lymphocytic Leukemia</keyword>
</DOC>